NCT01304277已完成2 期
A Phase II Comparability Study Between Replagal® Produced From Agalsidase Alfa Manufactured by 2 Different Processes in Adult Male Patients With Fabry Disease
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Shire
- 入组人数
- 17
- 试验地点
- 10
- 主要终点
- Change From Baseline to Week 16 (EOS) in Urine Gb3 Levels
研究概览
简要总结
This study is designed to evaluate safety and PK/PD in Canadian Fabry patients.
详细描述
In 2008, a change in the agalsidase alfa drug substance manufacturing process was made. There are no changes to the drug product formulation, manufacturing site, manufacturing process, or container closure.
An agalsidase alfa bioreactor manufacturing process (agalAF1) utilizing animal component-free media replaced the previous roller bottle (RB) process.
This study is designed to provide PD/PK and safety data. The assessment schedule is designed to capture the PK profile of drug uptake in the blood as well the pharmacologic effect which manifests over the course of weeks. Each patient will serve as his own control.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •The patient must be diagnosed with Fabry disease using the following criteria: The patient is a hemizygous male with Fabry disease as confirmed by a deficiency of α-galactosidase A activity measured in serum, leukocytes, or fibroblasts or has a confirmed mutation of the α-galactosidase A gene.
- •Patient is male and between 18 and 65 years of age, inclusive.
- •Patient must be willing to remain in the clinic as required by the study and comply with the procedures and evaluations of the study.
- •At the time of confirmation of study eligibility visit, patients must have received at least 26 weeks of treatment with RB Replagal at a dose of 0.2 mg/kg administered IV EOW.
- •Patient provides informed consent.
- •Patients who are naive to ERT:
- •Treatment naive patients must have a pretreatment plasma Gb3 level above the normal range (if value is available).
排除标准
- •Patient is unable to be venipunctured and/or tolerate venous access.
- •Patient has tested positive for anti-agalsidase alfa antibodies either at screening or confirmation of eligibility visit.
- •Patient had pre-ERT plasma Gb3 levels within the normal range (if value is available).
- •Patient is participating in any other Shire HGT investigational study.
- •Patient is currently on dialysis, is expected to begin dialysis during the study, has received a kidney transplant, or is on the renal transplant waiting list.
- •Patient is unable to comply with the protocol (eg, clinical relevant medical condition making implementation of the protocol difficult, unstable social situation, or otherwise unlikely to complete the study) or is, in the opinion of the Investigator, otherwise unsuited for the study.
- •The patient is enrolled in another clinical study that involves clinical investigations or use of any investigational product (drug or device), except for the Canadian Fabry Disease Initiative, within 6 months prior to receiving the first dose of AF Replagal in this study or at any time during the study.
- •The patient has previously received AF Replagal prior to study entry.
结局指标
主要结局
Change From Baseline to Week 16 (EOS) in Urine Gb3 Levels
时间窗: Baseline to EOS
次要结局
- Change From Baseline to Week 16 (EOS) in Plasma Gb3 Levels(Baseline to EOS)
- Dose-normalized AUC Extrapolated to Infinity (AUC∞/Dose)(Week 0 to Week 14)
- Overall Summary of TEAEs by Treatment (Replagal RB and Replagal AF)(Week 2 to EOS)
- To Assess Safety and Tolerability by Anti-agalsidase Alfa Antibody Status (in Serum) at End of Study(EOS)
- Dose-normalized Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Sample (AUClast/Dose)(Week 0 to Week 14)
- Dose-normalized Maximum Serum Concentration (Cmax/Dose)(Week 0 to Week 14)
研究者
研究点 (10)
Loading locations...
相似试验
已完成
2 期
Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC) in Patients With Stable Type 2 Diabetes and HypertensionHypertensionDiabetes Mellitus, Type 2NCT03091920Cyclerion Therapeutics26
已完成
1 期
A Safety and Pharmacokinetic Study Between HLX02 and Herceptin®(US-licensed and EU-approved) in Healthy Chinese Male SubjectsHealthyNCT04670796Shanghai Henlius Biotech111
已完成
2 期
Remegal Different Doses in Patients With Refractory Partial SeizuresDrug SafetyNormal Drug ToleranceSelf EfficacyNCT01179854Valexfarm60
已完成
2 期
Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 DiabetesDiabetes Mellitus, Type 2NCT01338870Pfizer301
进行中（未招募）
1 期
A Study of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese ParticipantsHealthy VolunteersNCT06139055Gasherbrum Bio, Inc70